{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=68", "query": { "condition": "Relapse Leukemia", "page": 68 }, "page_size": 10 }, "pagination": { "page": 68, "page_size": 10, "total_count": 1826, "total_pages": 183, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=69&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=67&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T02:08:21.088Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01643603", "title": "Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Hodgkin's Lymphoma", "Myeloid Leukemia", "Multiple Myeloma", "Myelodysplastic Syndrome", "Lymphoid Leukemia" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2012-05", "completion_date": "2018-10-09", "has_results": false, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-11-12T02:08:21.088Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01643603" }, { "nct_id": "NCT01929720", "title": "Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anxiety Disorder", "Worry", "Uncertainty", "Sleep Disorders", "Insomnia", "Fatigue", "Pain", "Depression", "Cognitive-behavioral Therapy", "Psychological Intervention", "Esophageal Cancer", "Pancreatic Cancer", "Leukemia", "Lung Cancer", "Multiple Myeloma", "Ovarian Neoplasm", "Stage III or IV Cervical or Uterine Cancer", "Stage IIIB, IIIC, or IV Breast Cancer", "Glioblastoma Multiforme", "Relapsed Lymphoma", "Stage III or IV Colorectal Cancer", "Stage IIIC or IV Melanoma" ], "interventions": [ { "name": "Cognitive-behavioral therapy for worry, uncertainty & insomnia", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2011-08", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2017-04-05", "last_synced_at": "2026-11-12T02:08:21.088Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01929720" }, { "nct_id": "NCT04017546", "title": "CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML", "MDS" ], "interventions": [ { "name": "CYC065", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cyclacel Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2019-08-02", "completion_date": "2023-04-05", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-11-12T02:08:21.088Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04017546" }, { "nct_id": "NCT01700946", "title": "Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood B-Lymphoblastic Lymphoma" ], "interventions": [ { "name": "dexamethasone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "clofarabine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "pegaspargase", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "mitoxantrone", "type": "DRUG" }, { "name": "teniposide", "type": "DRUG" }, { "name": "vinblastine", "type": "DRUG" }, { "name": "natural killer cell infusion", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "CliniMACS", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "PROCEDURE", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 80, "start_date": "2013-04-15", "completion_date": "2021-07-24", "has_results": true, "last_update_posted_date": "2022-09-28", "last_synced_at": "2026-11-12T02:08:21.088Z", "location_count": 3, "location_summary": "San Diego, California • Memphis, Tennessee • Fort Worth, Texas", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01700946" }, { "nct_id": "NCT02071927", "title": "Study of the Glutaminase Inhibitor CB-839 in Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Acute Lymphocytic Leukemia (ALL)" ], "interventions": [ { "name": "CB-839", "type": "DRUG" }, { "name": "CB-Aza", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2014-03", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2017-02-09", "last_synced_at": "2026-11-12T02:08:21.088Z", "location_count": 5, "location_summary": "Denver, Colorado • Chicago, Illinois • Buffalo, New York + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Buffalo", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02071927" }, { "nct_id": "NCT02264873", "title": "Phase I, Dose Escalation Study of Decitabine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Lymphoblastic, Acute", "Leukemia, Myeloid Acute", "Hematopoetic Myelodysplasia" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 3, "start_date": "2014-10", "completion_date": "2018-09-18", "has_results": false, "last_update_posted_date": "2018-10-15", "last_synced_at": "2026-11-12T02:08:21.088Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02264873" }, { "nct_id": "NCT01199575", "title": "Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "CLL" ], "interventions": [ { "name": "Revlimid", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2010-08", "completion_date": "2022-07-19", "has_results": true, "last_update_posted_date": "2024-08-15", "last_synced_at": "2026-11-12T02:08:21.088Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01199575" }, { "nct_id": "NCT01289457", "title": "Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Clofarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 282, "start_date": "2011-02-02", "completion_date": "2017-06-28", "has_results": true, "last_update_posted_date": "2020-02-24", "last_synced_at": "2026-11-12T02:08:21.088Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01289457" }, { "nct_id": "NCT04771572", "title": "Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Hodgkin Lymphoma", "Richter Transformation", "Multiple Myeloma", "T-cell-prolymphocytic Leukemia", "Acute Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Myeodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm", "Myelofibrosis", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Chronic Myelomonocytic Leukemia-2", "Myelodysplastic Neoplasm in Blast Phase" ], "interventions": [ { "name": "LP-118", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Newave Pharmaceutical Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 100, "start_date": "2022-05-08", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-11-12T02:08:21.088Z", "location_count": 8, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Chapel Hill, North Carolina + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04771572" }, { "nct_id": "NCT01037556", "title": "PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia" ], "interventions": [ { "name": "PR104", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Proacta, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2010-01", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2012-08-31", "last_synced_at": "2026-11-12T02:08:21.088Z", "location_count": 2, "location_summary": "Houston, Texas • Seattle, Washington", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01037556" } ] }